Impact of Major Complications on Patients' Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Ann Surg Oncol 2016 09 19;23(9):2946-52. Epub 2016 Apr 19.

Division of General Surgery, Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.

Introduction: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is an effective treatment for selected patients with peritoneal surface malignancies (PSM). Although it can have significant morbidity, perioperative mortality is low. Little is known about whether major complications after CRS/HIPEC have a lasting impact on patients' quality of life (QOL).

Methods: We retrospectively reviewed data from a prospectively collected database on patients treated with CRS/HIPEC for PSM (2011-2014). Patients with CRS/HIPEC and 6-month QOL evaluation were included. Major perioperative complications (Clavien-Dindo grade 3/4) were the primary independent variable. QOL was evaluated using the validated EORTC QLQ-C30 score. The primary outcome was 6-month global health score. Secondary outcomes were individual functional and symptom domains.

Results: Forty-two patients were analyzed. Median age was 57.5; 64 % were female. Origin of PSM was appendix (55 %), colorectal (38 %), mesothelioma (5 %), and small bowel (2 %). Fourteen patients (33 %) had major (grade 3/4) complications. Median length of stay was 16 days; patients experiencing major complications had significantly increased length of stay (35.5 vs. 13 days, p < 0.01). Major complications included intra-abdominal abscess (9.5 %), bleeding (9.5 %), symptomatic pleural effusion (7.1 %), anastomotic leaks (7.1 %), and renal failure (2.4 %). The average global health score at 6 months was 68.1. The worst-rated symptom scores at 6 months were diarrhea (39.8) and fatigue (35.4). There were no significant differences in 6-month QOL scores between patients with and without major complications, globally or in specific domains.

Conclusions: Although major complications are common after CRS/HIPEC, QOL at 6 months recovers and is similar to those without major complications.

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-016-5231-2DOI Listing
September 2016
6 Reads

Publication Analysis

Top Keywords

major complications
12
cytoreductive surgery
8
quality life
8
hyperthermic intraperitoneal
8
patients' quality
8
intraperitoneal chemotherapy
8
length stay
8
grade 3/4
8
patients
6
complications
5
evaluation included
4
included major
4
patients crs/hipec
4
64 % female
4
2011-2014 patients
4
575 64 %
4
psm 2011-2014
4
median age
4
age 575
4
6-month qol
4

References

(Supplied by CrossRef)

J Segelman et al.
Br J Surg. 2012

DG Jayne et al.
Br J Surg. 2002

VJ Verwaal et al.
Ann Surg Oncol. 2008

TC Chua et al.
J Clin Oncol. 2012

O Glehen et al.
Cancer. 2010

EA Levine et al.
J Am Coll Surg. 2014

RP McQuellon et al.
Eur J Surg Oncol. 2001

TM Tuttle et al.
Ann Surg Oncol. 2006

RP McQuellon et al.
Ann Surg Oncol. 2007

CS Chia et al.
Eur J Surg Oncol. 2014

R McQuellon et al.
J Surg Oncol. 2008

Similar Publications